ASH 2021 | Identifying low- and high-risk AML
Curtis Lachowiez
• 2 Dec 2021
Curtis Lachowiez, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the identification of high- and low-risk acute myeloid leukemia (AML). Patients are risk stratified at diagnosis based on morphologic, cytogenetic, and molecular genetic information. Various genetic alterations are typically associated with a different risk stratification: good, intermediate, or adverse. Dr Lachowiez discusses common mutations used to classify patients. Clinical characteristics are also considered, with secondary, therapy-related, and relapsed AML also regarded as high-risk. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
